New dermal collaboration on XF-73
Destiny Pharma has announced a new clinical programme that is planned to start in China, led by its existing partner China Medical Systems Limited (CMS). Destiny already has an earlier stage (than its two Phase 3-ready programmes) dermal programme on XF-73, but for serious infections of burns and open wounds. This new programme is to be run by CMS for the larger market of the prevention and treatment of superficial bacterial skin infections.While investors may have forgotten CMS’s involvement, this type of collaboration may have been part of the original deal, hence financial terms were not disclosed. CMS already has a portfolio of dermatology assets which it sells via its sales and marketing infrastructure in China, so knows this therapeutic market in China - and its unmet needs - well.
In addition, the treatment of primary skin infections (like impetigo, which is not associated with injury), and secondary superficial skin infections (which are), are very large markets. What gives Destiny’s XF-73 product an advantage is the potential for the prevention of superficial skin infections noted in the announcement.
We have left our financials and valuation for Destiny unchanged for the moment, despite the recent CMS collaboration. Our fair value of Destiny Pharma remains at £200.2m or 335p per share.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.